At EBMT 2025, Dr. Nicoletta Cieri (Dana-Farber Cancer Institute) delivered a forward-looking presentation exploring the prognostic potential of mHAg load in allogeneic hematopoietic cell transplantation (allo-HCT).
Her findings suggest that systematic prediction of mHAgs is not only feasible and scalable, but may also enhance graft-versus-host disease (GvHD) prognostication and guide personalized risk mitigation strategies—especially for high-risk patients. Ongoing research is evaluating whether mHAg load could serve as a universal predictor of GvHD risk across diverse transplant settings, including unrelated donors (URD), haploidentical transplants, and PTCy platforms.
This approach may pave the way toward more refined donor selection algorithms and truly individualized transplant planning.
Many thanks to Dr. Cieri for this thought-provoking presentation!
For more insights, visit: https://lnkd.in/dzCKPt-z
